Alim Hossen

Alim Hossen

Auto-generated profile, based on publicly available information

Alim Hossen

Department of Physical Sciences, Independent University, Bangladesh, Dhaka, Bangladesh

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
AHAlim Hossen
Alim Hossen
SRSelim Reza
Selim Reza
HRHarun- Or- Roshid
Harun- Or- Roshid
MIMd. Ariful Islam
Md. Ariful Islam
MSMst. Ayesha Siddika
Mst. Ayesha Siddika
MMMd. Nurul Haque Mollah
Md. Nurul Haque Mollah
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally. The mechanisms underlying the development of HCC are mostly unknown till now. Objective: The main goal of this study was to identify potential drug target proteins and agents for the treatment of HCC. Methods: The publicly available three independent mRNA expression profile datasets were downloaded from the NCBI-GEO database to explore common differentially expressed genes (cDEGs) between HCC and control samples using the Statistical LIMMA approach. Hub-cDEGs as drug targets highlighting their functions, pathways, and regulators were identified by using integrated bioinformatics tools and databases. Finally, Hub-cDEGs-guided top-ranked drug agents were identified by molecular docking study for HCC. Results: We identified 160 common DEGs (cDEGs) from three independent mRNA expression datasets in which ten cDEGs (CDKN3, TK1, NCAPG, CDCA5, RACGAP1, AURKA, PRC1, UBE2T, MELK, and ASPM) were selected as Hub-cDEGs. The GO functional and KEGG pathway enrichment analysis of Hub-cDEGs revealed some crucial cancer-stimulating biological processes, molecular functions, cellular components, and signaling pathways. The interaction network analysis identified three TF proteins and five miRNAs as the key transcriptional and post-transcriptional regulators of HubcDEGs. Then, we detected the proposed Hub-cDEGs guided top-ranked three anti-HCC drug molecules (Dactinomycin, Vincristine, Sirolimus) that were also highly supported by the already published top-ranked HCC-causing Hub-DEGs mediated receptors. Conclusion: The findings of this study would be useful resources for diagnosis, prognosis, and therapies of HCC.

1 January 2025 in International Journal of Breast Cancer
Verified
Journal Article
Open access
SBSm Faysal Bellah
Sm Faysal Bellah
AHAlim Hossen
Alim Hossen
SBS. M. Saker Billah
S. M. Saker Billah
NINur Islam
Nur Islam
Background: Breast cancer is a leading cause of cancer‐related morbidity and mortality in women worldwide. Among its subtypes, triple‐negative breast cancer (TNBC) poses the greatest therapeutic challenge due to its aggressive nature and lack of targeted treatments. Holocytochrome c synthase (HCCS), a mitochondrial enzyme essential for cytochrome c maturation, may play a pivotal role in cancer pathogenesis. Objective: This study aimed to investigate the expression profile, epigenetic regulation, immune interactions, prognostic significance, and molecular networks of HCCS across cancers, with a particular focus on breast cancer and its subtypes. Methods: Publicly available datasets and bioinformatics tools were employed to analyze HCCS expression, methylation, survival outcomes, immune infiltration, and interaction networks. Expression and clinical outcomes were examined using TCGA, while methylation and expression patterns were assessed via UALCAN and TNMplot. Survival analyses were performed using Kaplan–Meier Plotter, and immune infiltration was evaluated with TIMER2.0. Protein–protein interaction networks were generated with STRING, and functional enrichment was conducted through g:Profiler. Key findings were validated in independent breast cancer cohorts from GEO and the GOBO platform. Results: HCCS was significantly overexpressed in multiple cancers, with the highest upregulation observed in breast cancer, particularly TNBC. Hypomethylation of the HCCS promoter was associated with increased expression. High HCCS expression correlated with poorer relapse‐free survival and greater immune infiltration, including CD4 + T cells, CD8 + T cells, macrophages (M1/M2), mast cells, and regulatory T cells. Protein–protein interaction analysis revealed HCCS‐associated genes enriched in mitochondrial and apoptotic pathways. Validation across independent datasets consistently supported the association of elevated HCCS expression with poor prognosis in breast cancer. Conclusion: This integrated bioinformatics analysis highlights HCCS as a potential prognostic biomarker and therapeutic target in breast cancer, particularly in TNBC, although further experimental validation is required before clinical application.

26 March 2026 in Cancer Biomarkers
Verified
Journal Article
Open access
SBSm Faysal Bellah
Sm Faysal Bellah
AHAlim Hossen
Alim Hossen
SBS.M. Saker Billah
S.M. Saker Billah
Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Holocytochrome c synthase (HCCS), a mitochondrial enzyme involved in apoptosis and energy metabolism, has been implicated in tumorigenesis; however, its role in lung cancer is not well defined. Aim: This study aimed to elucidate the prognostic and therapeutic potential of HCCS in lung cancer through integrative bioinformatics analyses. Methods: Transcriptomic, methylation, and clinical data from TCGA were analyzed using TNMplot, UALCAN, and TIMER2.0 to evaluate HCCS expression, promoter methylation, immune infiltration, and prognostic relevance in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Meta-analysis of 18 independent cohorts from LUNG CANCER EXPLORER and four GEO datasets validated expression patterns, while Kaplan–Meier analysis assessed survival outcomes. Results: HCCS was significantly upregulated in LUAD and LUSC and showed promoter hypermethylation in LUAD. Meta-analysis and external validation confirmed its overexpression. Patients with low HCCS expression exhibited poorer overall survival, suggesting a potential tumor-suppressive effect. HCCS expression positively correlated with immune cell infiltration and co-expressed genes enriched in mitochondrial and apoptotic pathways. Conclusion: HCCS may serve as a prognostic and therapeutic biomarker in lung cancer, linking mitochondrial regulation, epigenetic modification, and immune interactions.